Twist BioscienceTWST
TWST
About: Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Employees: 923
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
70% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 27
60% more call options, than puts
Call options by funds: $3.36M | Put options by funds: $2.11M
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
13% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 80
6% more funds holding
Funds holding: 245 [Q4 2024] → 259 (+14) [Q1 2025]
4.04% more ownership
Funds ownership: 111.48% [Q4 2024] → 115.52% (+4.04%) [Q1 2025]
12% less capital invested
Capital invested by funds: $3.08B [Q4 2024] → $2.71B (-$378M) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
2%
downside
Avg. target
$44
31%
upside
High target
$50
49%
upside
5 analyst ratings
4 positive
80%
0 neutral
0%
1 negative
20%
Goldman Sachs Matthew Sykes | 43%upside $48 | Buy Maintained | 6 May 2025 |
Guggenheim Subbu Nambi | 49%upside $50 | Buy Reiterated | 6 May 2025 |
Baird Catherine Ramsey | 31%upside $44 | Outperform Maintained | 6 May 2025 |
JP Morgan Rachel Vatnsdal | 2%downside $33 | Underweight Maintained | 6 May 2025 |
Barclays Luke Sergott | 34%upside $45 | Overweight Maintained | 10 Apr 2025 |
Financial journalist opinion
Neutral
Business Wire
3 weeks ago
Twist Bioscience and Element Biosciences Expand Collaboration to Transform Next Generation Sequencing Workflows with Co-Developed End-to-End Solutions
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. “This collaboration bu.
Neutral
Business Wire
1 month ago
Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor.
Neutral
Business Wire
1 month ago
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units (“RSUs”) and up to 19,379 performance stock units (“PSUs”), to 36 recently hired individuals, in each case as an.
Neutral
Business Wire
1 month ago
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agr.
Negative
Seeking Alpha
1 month ago
Twist Bioscience: Expansion Efforts Continue To Face Challenges
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will help to reduce cash burn. The transaction attributes a fairly modest valuation to the business, though. This comes after the recent struggles of the biopharma business and a royalty sale, which suggests the biopharma business hasn't created much value so far.
Neutral
Seeking Alpha
1 month ago
Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. Thank you for standing by.
Negative
Zacks Investment Research
1 month ago
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago.
Neutral
Business Wire
1 month ago
Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report a.
Neutral
Business Wire
1 month ago
Twist Bioscience Spins Out DNA Data Storage as Independent Company
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage (“Atlas”). “There are many applications of synthetic DNA with the potential to have an incredible impact on the world. With this spin out, both Twist and Atlas are.
Positive
Seeking Alpha
1 month ago
Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers
Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, Twist's stock has experienced sharp declines post-earnings on underwhelming financials. 2025 guidance shows ~20% revenue growth, but the market remains skeptical of Twist's ability to achieve profitability, leading to my downgrade from "Buy" to "Hold".
Charts implemented using Lightweight Charts™